Climb Bio (CLYM) Research & Development (2020 - 2026)

Climb Bio has reported Research & Development for 7 years, with the latest figure at $9.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 45.91% year-over-year to $9.4 million; the trailing twelve-month figure through Mar 2026 stood at $38.8 million (up 26.78% YoY), and the FY2025 full-year result was $46.7 million, up 225.84% from the prior year.
• Research & Development for Q1 2026 stood at $9.4 million, down from $13.7 million in the prior quarter.
• The five-year high for Research & Development was $17.3 million in Q1 2025, with the low at $1.0 million in Q2 2024.
• Historically, Research & Development has averaged $6.6 million across 5 years, with a median of $6.0 million in 2024.
• Annual changes were most pronounced in 2024 — Research & Development plunged 80.93% — and 2025, when it soared 1488.18%.
• Climb Bio's Research & Development stood at $4.9 million in 2022, then slumped by 36.53% to $3.1 million in 2023, then surged by 90.57% to $6.0 million in 2024, then jumped by 130.54% to $13.7 million in 2025, then tumbled by 31.77% to $9.4 million in 2026.
• The last three Research & Development figures came in at $9.4 million (Q1 2026), $13.7 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.